Transitional cell carcinoma of the prostate

Cheville, John C.; Dundore, Paul A.; Bostwick, David G.; Lieber, Michael M.; Batts, Kenneth P.; Sebo, Thomas J.; Farrow, George M.

doi:10.1002/(sici)1097-0142(19980215)82:4<703::aid-cncr13>3.0.co;2-1

Cited by 68 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For advanced-stage PUC, gemcitabine combined with cis-platinum is the first-line chemotherapy regimen. 9 Cheville et al 10 reported primary PUC with a poor prognosis and 5-year survival rate of 52%. Ichihara et al’s 11 study suggested that primary PUC patients with stromal invasion or lymph node metastasis have worse prognosis.…”

Section: Discussionmentioning

confidence: 99%

Case report of a primary prostatic urothelial carcinoma patient with sustained fever

Zhang

Guo

2018

OTT

View full text Add to dashboard Cite

A 77-year-old-male patient presented with recurrent gross hematuria for 3 months with a fever for 1 month, and so was admitted to The First Hospital of Tsinghua University. The medical history revealed the patient exhibited no symptoms of night sweat, dysuria, or abdominal pain. The patient experienced sustained fever with maximal temperature of 39°C for 1 month without any infectious symptoms. The biochemical examination revealed that renal and hepatic function tests were normal. Serum prostate-specific antigen and free prostate-specific antigen were at a normal level. Enhanced computed tomography and magnetic resonance imaging was performed and indicated prostatic cancer with bilateral pulmonary metastases. Subsequently, prostatic urothelial carcinoma was confirmed by a histopathology assay of the prostate biopsy. Following 1 course of chemotherapy, the temperature of the patient returned to normal.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report of a primary prostatic urothelial carcinoma patient with sustained fever

Zhang

Guo

2018

OTT

View full text Add to dashboard Cite

show abstract

“…This chemotherapy caused a marked regression of the prostate tumor and the secondary urethral lesion. Although the standard radical operation for TCC of the prostate may be cysto-prostatectomy, 7 we performed radical prostatectomy due to the marked effectiveness of the chemotherapy. The residual prostate tumor consists of PSA-positive, moderately differentiated adenocarcinoma similar to a papillary adenocarcinoma of ductal origin.…”

Section: Discussionmentioning

confidence: 99%

Adenocarcinoma arising from the prostatic duct mimicking transitional cell carcinoma

Οhyama

Takyu²,

Yoshikawa³

et al. 2001

Int J of Urology

View full text Add to dashboard Cite

A 71-year-old man was first diagnosed with primary transitional cell carcinoma of the prostate with a skip lesion on the distal urethra. The patient received three courses of intra-arterial chemotherapy of cisplatin (CDDP) and pirarubicin (THP-ADM) followed by a radical prostatectomy. Histopathologic examination of the prostatectomy specimen revealed adenocarcinoma invasion along the prostatic duct extending to the peripheral acini, which was diagnosed as ductal adenocarcinoma. The clinical and histopathologic features of this case are entirely different from usual adenocarcinomas of the prostate. This rare histopathologic feature should be recognized as 'ductal carcinoma of the prostate', to distinguish it from papillary adenocarcinoma or adenocarcinoma with endometrioid features. The patient has had no sign of recurrence 14 months after the operation. CDDP-based chemotherapy followed by radical prostatectomy may be one of the promising therapeutic modalities for this rare entity.

show abstract

“…Prostatic urothelial carcinoma can arise from the urothelium of the prostatic urethra and the proximal portions of the prostatic ducts [1–3, 70]. Most cases of prostatic urothelial carcinoma present concurrently with bladder carcinoma.…”

Section: The 2016 Who Classificationmentioning

confidence: 99%

“…Prostatic urothelial carcinoma has a marked propensity for growth within prostatic ducts and acini with solid cylinders, with or without comedo necrosis [1–3, 70]. The tumor cells exhibit marked nuclear pleomorphism with numerous mitoses.…”

Section: The 2016 Who Classificationmentioning

confidence: 99%

See 1 more Smart Citation

Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification

Inamura

2018

Oncotarget

View full text Add to dashboard Cite

Accumulating evidence suggests that prostatic cancers represent a group of histologically and molecularly heterogeneous diseases with variable clinical courses. In accordance with the increased knowledge of their clinicopathologies and genetics, the World Health Organization (WHO) classification of prostatic cancers has been revised. Additionally, recent data on their comprehensive molecular characterization have increased our understanding of the genomic basis of prostatic cancers and enabled us to classify them into subtypes with distinct molecular pathologies and clinical features. Our increased understanding of the molecular pathologies of prostatic cancers has permitted their evolution from a poorly understood, heterogeneous group of diseases with variable clinical courses to characteristic molecular subtypes that allow the implementation of personalized therapies and better patient management. This review provides perspectives on the new 2016 WHO classification of prostatic cancers as well as recent knowledge of their molecular pathologies. The WHO classification of prostatic cancers will require additional revisions to allow for reliable and clinically meaningful cancer diagnoses as a better understanding of their molecular characteristics is obtained.

show abstract

Transitional cell carcinoma of the prostate

Abstract: This study demonstrates that patients with prostatic TCC involving prostatic stroma, extraprostatic tissues, seminal vesicles, and lymph nodes have a significantly poorer 5-year disease specific survival than patients with CIS.

Cited by 68 publications

References 11 publications

Case report of a primary prostatic urothelial carcinoma patient with sustained fever

Case report of a primary prostatic urothelial carcinoma patient with sustained fever

Adenocarcinoma arising from the prostatic duct mimicking transitional cell carcinoma

Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification

Contact Info

Product

Resources

About